0.692
0.00 (-0.17%)
Previous Close | 0.693 |
Open | 0.720 |
Volume | 31,040 |
Avg. Volume (3M) | 207,140 |
Market Cap | 96,383,656 |
Price / Sales | 0.710 |
Price / Book | 1.72 |
52 Weeks Range | |
Earnings Date | 7 Aug 2025 |
Profit Margin | -9.81% |
Operating Margin (TTM) | 3.23% |
Diluted EPS (TTM) | -0.090 |
Quarterly Revenue Growth (YOY) | 18.10% |
Total Debt/Equity (MRQ) | 78.16% |
Current Ratio (MRQ) | 2.34 |
Operating Cash Flow (TTM) | -4.86 M |
Levered Free Cash Flow (TTM) | -5.48 M |
Return on Assets (TTM) | -4.97% |
Return on Equity (TTM) | -26.19% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Bearish | Bearish |
Medical Devices (Global) | Bearish | Bearish | |
Stock | Xtant Medical Holdings, Inc. | - | - |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | -4.5 |
Technical Moving Averages | -2.5 |
Technical Oscillators | 2.5 |
Average | -1.63 |
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. |
|
Sector | Healthcare |
Industry | Medical Devices |
% Held by Insiders | 14.69% |
% Held by Institutions | 57.57% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
12 Aug 2025 | Announcement | Xtant Medical Reports Second Quarter 2025 Financial Results |
06 Aug 2025 | Announcement | Xtant Medical to Attend the CG 45th Annual Growth Conference |
05 Aug 2025 | Announcement | Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025 |
28 Jul 2025 | Announcement | Xtant Medical Partners With B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market Opportunity |
08 Jul 2025 | Announcement | Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine |
08 Jul 2025 | Announcement | Companion Spine LLC Announces Definitive Agreement to Acquire the Business and Assets of Paradigm Spine GmbH and the Coflex® and CoFix® Spine Implants from Xtant™ Medical Holdings, Inc. |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |